Q3 EPS Forecast for Foghorn Therapeutics Boosted by Analyst

Key Points

• Wedbush has increased its earnings estimates for Foghorn Therapeutics, predicting a Q3 2025 EPS of ($0.29), up from a previous estimate of ($0.33).
• Foghorn Therapeutics recently reported an EPS of ($0.28), which exceeded the consensus estimate of ($0.31), while revenue was $7.56 million, slightly below expectations.
• The company's stock has a current market cap of $273.13 million, with an average rating of "Buy" from analysts and a price target of $12.13.

Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Research analysts at Wedbush boosted their Q3 2025 earnings estimates for Foghorn Therapeutics in a note issued to investors on Tuesday, August 5th. Wedbush analyst R. Driscoll now forecasts that the company will post earnings of ($0.29) per share for the quarter, up from their prior estimate of ($0.33). The consensus estimate for Foghorn Therapeutics' current full-year earnings is ($1.55) per share. Wedbush also issued estimates for Foghorn Therapeutics' Q4 2025 earnings at ($0.23) EPS, FY2025 earnings at ($1.11) EPS, FY2026 earnings at ($0.95) EPS, FY2027 earnings at ($0.98) EPS, FY2028 earnings at ($0.57) EPS and FY2029 earnings at $0.62 EPS.

Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.03. The company had revenue of $7.56 million for the quarter, compared to analyst estimates of $7.62 million.

Other equities analysts also recently issued research reports about the stock. JMP Securities restated a "market outperform" rating and set a $9.00 price objective on shares of Foghorn Therapeutics in a report on Thursday, May 15th. HC Wainwright upgraded shares of Foghorn Therapeutics to a "strong-buy" rating in a report on Wednesday, May 14th. Citizens Jmp assumed coverage on shares of Foghorn Therapeutics in a report on Wednesday, April 23rd. They issued a "mkt outperform" rating and a $9.00 price target on the stock. Finally, Citigroup assumed coverage on shares of Foghorn Therapeutics in a report on Wednesday, April 23rd. They issued an "outperform" rating on the stock. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and two have assigned a strong buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $12.13.

Foghorn Therapeutics Stock Down 2.0%

FHTX opened at $4.90 on Thursday. Foghorn Therapeutics has a 52-week low of $2.94 and a 52-week high of $10.25. The company has a market cap of $273.13 million, a P/E ratio of -4.12 and a beta of 3.05. The firm's 50-day moving average price is $5.10 and its 200-day moving average price is $4.58.

Institutional Investors Weigh In On Foghorn Therapeutics

Hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its position in Foghorn Therapeutics by 14.5% in the 4th quarter. Bank of America Corp DE now owns 31,662 shares of the company's stock worth $149,000 after purchasing an additional 4,002 shares in the last quarter. D. E. Shaw & Co. Inc. boosted its position in Foghorn Therapeutics by 44.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 100,367 shares of the company's stock worth $474,000 after purchasing an additional 30,671 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in Foghorn Therapeutics in the 4th quarter worth approximately $61,000. Lazard Asset Management LLC purchased a new stake in Foghorn Therapeutics in the 4th quarter worth approximately $49,000. Finally, Geode Capital Management LLC boosted its position in Foghorn Therapeutics by 0.8% in the 4th quarter. Geode Capital Management LLC now owns 682,863 shares of the company's stock worth $3,224,000 after purchasing an additional 5,477 shares in the last quarter. Hedge funds and other institutional investors own 61.55% of the company's stock.

About Foghorn Therapeutics

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.